|Application ||WB, IHC|
|Calculated MW||85363 Da|
|Positive Control||Western blot: HeLa cells, ChIP: HeLa cells, IHC.|
|Application & Usage||ChIP: 2.5 µg/ChIP, Western Blot: 1:1000, IHC: 1:100 – 1:500.|
|Other Names||Enhancer of zeste homolog 2|
|Formulation||In PBS with 0.05% sodium azide and 0.05% ProClin 300.|
|Handling||The antibody solution should be gently mixed before use.|
|Reconstitution & Storage||-20 °C|
|Precautions||EzH2 polyclonal antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Polycomb group (PcG) protein. Catalytic subunit of the PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys- 27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. Displays a preference for substrates with less methylation, loses activity when progressively more methyl groups are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2 (PubMed:22323599). Compared to EZH1-containing complexes, it is more abundant in embryonic stem cells and plays a major role in forming H3K27me3, which is required for embryonic stem cell identity and proper differentiation. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A and retinoic acid target genes. EZH2 can also methylate non- histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. Regulates the circadian clock via histone methylation at the promoter of the circadian genes. Essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.|
|Tissue Location||Expressed in many tissues. Overexpressed in numerous tumor types including carcinomas of the breast, colon, larynx, lymphoma and testis.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EZH2 is a histone-lysine methyltransferase which methylates ‘Lys-9’ and ‘Lys-27’ of histone H3, leading to transcriptional repression. It is a member of the polycomb group (PcG) family which form multimeric protein complexes and are involved in maintaining the transcriptional repressive state of genes over successive cell generations. The EZH2 activity is dependent on the association with other components of the PRC2 complex (EED, EZH2, SUZ12/JJAZ1, RBBP4 and RBBP7). EZH2 may play a role in the hematopoietic and central nervous systems. Over-expression of EZH2 is observed during advanced stages of prostate cancer and breast cancer.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.